Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration

On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-Vax platform. The technology is a stalwart example of the Johns Hopkins Tech Transfer program, designed to develop new discoveries and inventions into products and services that benefit society.

Tuesday’s event also celebrated Maryland’s ability to nurture new life sciences companies by fostering a community devoted to biotechnology and innovation. Maryland boasts over 800 life science companies, 70 federal labs and unique access to regulatory agencies.

The event featured remarks from:

Tom August, MD, Distinguished Service Professor of Pharmacology and Molecular Sciences and Oncology, Johns Hopkins University School of Medicine, who developed the game-changing vaccine technology
Brian Stansky, FastForward Director, Johns Hopkins University
Bill Hearl, Ph.D., Immunomic Therapeutics, Inc. CEO
Attendees also included Ben Wu, Deputy Secretary, Maryland Department of Commerce (DoC) and Drew Pardoll, M.D., Ph.D., Co-Director, Cancer Immunology and Hematopoiesis Program and Johns Hopkins community members.

About ARA-LAMP-Vax

Food allergies cause more than 30,000 cases of severe allergic reactions (anaphylaxis) and 100 to 200 deaths in the United States every year. A common and potentially serious food allergy is to peanuts, which can cause potentially life-threatening anaphylaxis, even from trace exposures. Peanut allergies affect more than 1.5 million Americans who have to maintain constant dietary vigilance to reduce the risk of accidental peanut-induced anaphylaxis. There is no available peanut-specific treatment approved by the U.S Food and Drug Administration for peanut allergies. ARA-LAMP-vax has been developed based on LAMP-Vax platform, of which exclusive and worldwide license is granted to Immunomic Therapeutics by Johns Hopkins University. ARA-LAMP-Vax is a LAMP-based DNA vaccine that is designed to change the immune response to the major peanut allergens, with the goal of elimination of allergy symptoms.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company dedicated to pioneering vaccines that transform lives. Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI is developing next-generation vaccines based on patented LAMP Technology. Its LAMP-vax vaccine platform significantly increases the immune response to nucleic acid vaccines and simplifies vaccine design and delivery for safer, more cost-effective therapies. LAMP constructs have been validated in human clinical trials for cancer and have been applied to targets like allergy, cancer and infectious diseases. Immunomic Therapeutics’ vision is to have regulatory approved products in pollen allergy, food allergy, cancer, and animal health. For information about Immunomic Therapeutics and LAMP Technology, visit www.immunomix.com.